CINXE.COM

<?xml version="1.0" encoding="utf-8"?> <rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>PharmaVoice - Latest News</title><link>https://www.pharmavoice.com/news/</link><description>News for pharmacy pros</description><atom:link href="https://www.pharmavoice.com/feeds/news/" rel="self"></atom:link><language>en-us</language><lastBuildDate>Fri, 22 Nov 2024 07:35:41 -0500</lastBuildDate><item><title>Will Walgreens’ store closures derail its clinical trial aims?</title><link>https://www.pharmavoice.com/news/walgreens-earnings-clinical-trials-ramita-tandon/733660/</link><description><figure><div><img src="https://imgproxy.divecdn.com/S4s5bD6okwAca5z-TyL3nE1CfTKkg5ICKxMqsZi1Lss/g:nowe:0:0/c:1024:578/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xOTA3NzI4Mzk0X1pPcElvNkEuanBn.webp"/></div></figure><p>Despite a plan to shutter&nbsp;1,200 stores, the company&rsquo;s chief clinical trials officer said the pharmacy juggernaut remains committed to drug research.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Meagan Parrish</dc:creator><pubDate>Fri, 22 Nov 2024 07:35:41 -0500</pubDate><guid>https://www.pharmavoice.com/news/walgreens-earnings-clinical-trials-ramita-tandon/733660/</guid></item><item><title>Pfizer, under pressure to change, names oncology head as new R&D chief</title><link>https://www.pharmavoice.com/news/pfizer-chris-boshoff-research-development-dolsten-successor/733488/</link><description><figure><div><img src="https://imgproxy.divecdn.com/jQ_5Zg_Ho64m_MJfxtpQ3m-Akr_tdECWcnW-WlOnR2g/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDkxNDg0MDMxLmpwZw==.webp"/></div></figure><p>Chris Boshoff will replace Mikael Dolsten, who&rsquo;s stepping down after 15 years leading research at the drugmaker.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kristin Jensen</dc:creator><pubDate>Thu, 21 Nov 2024 07:13:08 -0500</pubDate><guid>https://www.pharmavoice.com/news/pfizer-chris-boshoff-research-development-dolsten-successor/733488/</guid></item><item><title>Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals</title><link>https://www.pharmavoice.com/news/merck-keytruda-cancer-oncology-subcutaneous-roche-bristol-myers/733544/</link><description><p>A subcutaneous version of Merck&rsquo;s Keytruda was as effective as the infused version in a late-stage study, but the company won&rsquo;t be the first to market.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael Gibney</dc:creator><pubDate>Thu, 21 Nov 2024 07:12:57 -0500</pubDate><guid>https://www.pharmavoice.com/news/merck-keytruda-cancer-oncology-subcutaneous-roche-bristol-myers/733544/</guid></item><item><title>What might a Trump administration mean for the Biosecure Act?</title><link>https://www.pharmavoice.com/news/trump-congress-biosecure-act-china/733414/</link><description><figure><div><img src="https://imgproxy.divecdn.com/0d6RhFtGVYYDNQXlyu0UwrPEXqx4sTXNSIFghkOaQlo/g:nowe:0:0/c:1024:578/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTgzMjE2NTAyLmpwZw==.webp"/></div></figure><p>It&rsquo;s still likely U.S. biotechs and pharmas will have to cut ties with key Chinese partners &mdash; it&rsquo;s just a matter of when.</p> <p>&nbsp;</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Amy Baxter</dc:creator><pubDate>Wed, 20 Nov 2024 08:00:00 -0500</pubDate><guid>https://www.pharmavoice.com/news/trump-congress-biosecure-act-china/733414/</guid></item><item><title>What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine</title><link>https://www.pharmavoice.com/news/abbvie-cure-hiv-jochen-salfeld/733298/</link><description><p>AbbVie&rsquo;s head of R&amp;D cures has lofty ambitions to end diseases like HIV through a community of researchers that work as one.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael Gibney</dc:creator><pubDate>Tue, 19 Nov 2024 08:00:00 -0500</pubDate><guid>https://www.pharmavoice.com/news/abbvie-cure-hiv-jochen-salfeld/733298/</guid></item><item><title>The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate.</title><link>https://www.pharmavoice.com/news/annexon-guillain-barre-rare-disease-freddie-freeman/733266/</link><description><p>The company is looking to score an FDA nod for its investigational therapy that targets a molecule linked to Guillain-Barr&eacute; syndrome and other autoimmune diseases.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alexandra Pecci</dc:creator><pubDate>Tue, 19 Nov 2024 08:00:00 -0500</pubDate><guid>https://www.pharmavoice.com/news/annexon-guillain-barre-rare-disease-freddie-freeman/733266/</guid></item><item><title>Why Merck rolled the dice on an ‘unbelievable’ early-stage brain cancer drug</title><link>https://www.pharmavoice.com/news/merck-modifi-deal-glioblastoma-cancer/733102/</link><description><figure><div><img src="https://imgproxy.divecdn.com/k2vOOnhx7dA_O9KqZQmAKGFSZGN_yacMOnUD_wCVE84/g:nowe:0:36/c:594:336/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9nZXR0eWltYWdlcy03MjU2MTE2MS01OTR4NTk0LmpwZw==.webp"/></div></figure><p>Merck&rsquo;s acquisition of Modifi Biosciences bucks common M&amp;A trends in pharma.&nbsp;</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kelly Bilodeau</dc:creator><pubDate>Mon, 18 Nov 2024 07:53:58 -0500</pubDate><guid>https://www.pharmavoice.com/news/merck-modifi-deal-glioblastoma-cancer/733102/</guid></item><item><title>The first MASH drug could open the door for others — including GLP-1s</title><link>https://www.pharmavoice.com/news/mash-market-glp-1s-inventiva-pharma/733120/</link><description><figure><div><img src="https://imgproxy.divecdn.com/b20BnDEykJje5_zHVKMuYATtuhqhLqosJECk075Rxl0/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzkxODMyMDI2LmpwZw==.webp"/></div></figure><p>With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive edge.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Amy Baxter</dc:creator><pubDate>Mon, 18 Nov 2024 07:53:48 -0500</pubDate><guid>https://www.pharmavoice.com/news/mash-market-glp-1s-inventiva-pharma/733120/</guid></item><item><title>Trump names RFK Jr. as his pick to lead HHS</title><link>https://www.pharmavoice.com/news/trump-name-rfk-kennedy-hhs-secretary-nomination/733021/</link><description><figure><div><img src="https://imgproxy.divecdn.com/VEAKqV88QaAaZrLW3GestKSopI_YPZRHUAi3zNk1dJY/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTY3MjU2ODc0LmpwZw==.webp"/></div></figure><p>If confirmed to the role, Robert F. Kennedy Jr. would oversee the country&#39;s top health agencies, including the Food and Drug Administration and the Centers for Disease Control and Prevention.&nbsp;</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ned Pagliarulo</dc:creator><pubDate>Fri, 15 Nov 2024 07:09:46 -0500</pubDate><guid>https://www.pharmavoice.com/news/trump-name-rfk-kennedy-hhs-secretary-nomination/733021/</guid></item><item><title>Where are they now? 4 biotechs that soared then crashed during the pandemic</title><link>https://www.pharmavoice.com/news/biotech-covid-pandemic-inovio-curevac-novavax-veru/733007/</link><description><figure><div><img src="https://imgproxy.divecdn.com/dNaAvsxECv_A6rPgLZKqWPCOCNnMjMok9l18-zuoYAA/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTY1MTYwNDE0LmpwZw==.webp"/></div></figure><p>How Novavax and others have restructured and trudged forward after their COVID-era high.</p></description><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Meagan Parrish</dc:creator><pubDate>Fri, 15 Nov 2024 07:08:33 -0500</pubDate><guid>https://www.pharmavoice.com/news/biotech-covid-pandemic-inovio-curevac-novavax-veru/733007/</guid></item></channel></rss>